Baxter International Inc. BAX
23.37
(0.11)
(0.47%)
as of 25 Sep
- Market cap
- $12.2B
- P/E
- 0.0×
Follow BAX
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Baxter International Inc. (BAX) Return on equity
Baxter International Inc.'s return on equity over the twelve months to 30 June 2026 was −15.8%, down 1.2 percentage points from fiscal 2025 (−14.6%). Over the past ten years it has ranged from −32.4% (fiscal 2022) to 57.9% (fiscal 2016); the current reading is higher than 18% of that period. That is below the Medical Instruments & Supplies industry median of 0.00% and above the Healthcare sector median of −32.0%.
Return on equity, annual
Annual
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −14.6% | (6.20) |
| FY2024 | −8.38% | (45.36) |
| FY2023 | 37.0% | 69.39 |
| FY2022 | −32.4% | (46.80) |
| FY2021 | 14.4% | 1.14 |
| FY2020 | 13.3% | 0.56 |
| FY2019 | 12.7% | (5.52) |
| FY2018 | 18.2% | 11.29 |
| FY2017 | 6.92% | (51.00) |
| FY2016 | 57.9% | 46.55 |
Against its own ten years
Low −32.4%
High 57.9%
Ten-year median
12.7%
Current reading's percentile
18
Return on equity against peers
| Company | Return on equity |
|---|---|
| SOLV Solventum Corporation compare | 34.0% |
| ATR AptarGroup, Inc. compare | 13.5% |
| ALGN Align Technology, Inc. compare | 10.2% |
| STVN Stevanato Group S.p.A. compare | 9.21% |
| COO The Cooper Companies, Inc. compare | 6.84% |
| RGEN Repligen Corporation compare | 1.99% |
| BLCO Bausch + Lomb Corporation compare | −2.64% |
| AVTR Avantor, Inc. compare | −9.70% |
| BAX Baxter International Inc. | −15.8% |
| Medical Instruments & Supplies industry median | 0.00% |
| Healthcare sector median | −32.0% |
| Market median | 1.76% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)
More on BAX
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement